Thomas Wirth

from Wikipedia, the free encyclopedia

Thomas Wirth (born November 6, 1956 in Himmelstadt ) is a German biologist . He is dean of the Medical Faculty of the University of Ulm and Director of the Institute for Physiological Chemistry at the University of Ulm .

Career

Thomas Wirth attended secondary X-Gymnasium Würzburg and then completed his Abitur at the Friedrich-Koenig-Gymnasium in Wuerzburg He studied from 1976 to 1981 Biology at the University of Würzburg , where in 1985 he at the Institute of Virology and Immunobiology to the doctor Natural Sciences , Dr. rer. nat. PhD. From 1985 to 1987 he worked in the laboratory of David Baltimore at the Whitehead Institute for Biomedical Research in Cambridge and between 1988 and 1989 as a research assistant at the Institute for Immunology in Basel . In 1989 he started working as a research group leader at the Center for Molecular Biology at the University of Heidelberg (ZMBH) . Here he completed his habilitation in molecular biology in 1994 . In 1996 he returned to the University of Würzburg, where he was Professor of Molecular Genetics at the Institute for Medical Radiation and Cell Research in research and teaching until 1999 . In 1999 he accepted the chair for Physiological Chemistry at the University of Ulm and has been head of the institute of the same name ever since. During his time as Vice Dean (Deputy Dean) of the Medical Faculty of Ulm University from 2004 to 2010, he established the doctoral program in Experimental Medicine, which he is still responsible for coordinating. This program is part of the medical faculty's qualification concept for young scientists in medicine. Since 2010 he has been dean of the Medical Faculty of Ulm University. Thomas Wirth is co-founder of the German Trauma Foundation , initially as Vice President and since 2018 as President.

research

Wirth's research focus is on the investigation of the molecular basis of B-lymphocytes - differentiation and the development of B-cell tumors (lymphomas) . He also deals with the importance of the NF-kB signaling pathway for different diseases.

Awards

Publications

  • with L. Staudt and D. Baltimore: An octamer oligonucleotide placed upstream of a TATA motif is sufficient for lymphoid-specific promoter activity. In: Nature . 329, Sep 10, 1987, pp. 174-178. doi: 10.1038 / 329174a0 .
  • with T. Lernbecher and U. Müller: Distinct NF-κB / Rel transcription factors are responsible for tissue-specific and inducible gene activation. In: Nature. 365, Oct 21, 1993, pp. 767-770. doi: 10.1038 / 365767a0
  • with P. Pfisterer, A. Annweiler, C. Ullmer and LM Corcoran: Differential transactivation potential of Oct1 and Oct2 is determined by additional B-cell-specific activities. In: EMBO J. 13, Apr 1, 1994, pp. 1654-1663. PMC 394996 (free full text)
  • with S. Zwilling and H. König: HMG2 functionally interacts with the POU-domain of octamer transcription factors. In: EMBO J. 14, Mar 15, 1995, pp. 1198-1208. PMC 398197 (free full text)
  • with S. Zwilling, A. Dieckmann, P. Pfisterer and P. Angel: Inducible expression and phosphorylation of coactivator BOB.1 / OBF.1 in T cells. In: Science . 277, Jul 11, 1997, pp. 221-225. doi: 10.1126 / science.277.5323.221
  • with MA Huber, N. Azoitei, B. Baumann, S. Grünert, A. Sommer, H. Pehamberger, N. Kraut and H. Beug: NF-kB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. In: J.Clin.Invest. 114, Aug 16, 2004, pp. 569-581. doi: 10.1172 / JCI21358 .
  • with A. Ushmorov, F. Leithauser, O. Sakk, A. Weinhausel, SW Popov and P. Möller: Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. In: Blood . 107, Mar 15, 2006, pp. 2493-2500. doi: 10.1182 / blood-2005-09-3765 .
  • with B. Baumann, M. Wagner, T. Aleksic, G. von Wichert, CK Weber and G. Adler: Constitutive IKK2 activation in acinar cells is sufficient to induce pancreatitis in vivo. In: J.Clin.Invest. 117, Jun 1, 2007, pp. 1501-1513. doi: 10.1172 / JCI30876 .
  • with S. Sander, L. Bullinger, K. Klapproth, K. Fiedler, HA Kestler, TFE Barth, P. Möller, S. Stilgenbauer and JR Pollack: MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. In: Blood. 112, Nov 15, 2008, pp. 4202-4212. doi: 10.1182 / blood-2008-03-147645 .
  • with L. Xie, A. Ushmorov, F. Leithauser, H. Guan, C. Steidl, J. Farbinger, C. Pelzer, MJ Vogel, HJ Maier, RD Gascoyne and P. Möller: FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. In: Blood. 119, Apr 12, 2012, pp. 3503-3511. doi: 10.1182 / blood-2011-09-381905 .
  • with HJ Maier, TG Schips, A. Wietelmann, M. Krüger, C. Brunner, M. Sauter, K. Klingel, T. Böttger and T. Braun: Cardiomyocyte-specific IκB kinase (IKK) / NF-κB activation induces reversible inflammatory cardiomyopathy and heart failure. In: Proc.Natl.Acad.Sci USA . 109, Jul 17, 2012, pp. 11794-11799. doi: 10.1073 / pnas.1116584109 .

Individual evidence

  1. ^ Dean - Medical Faculty of Ulm University. Medical Faculty of the University of Ulm, accessed on March 3, 2016 .
  2. ^ Director - Institute for Physiological Chemistry at Ulm University. Medical Faculty of the University of Ulm, accessed on March 3, 2016 .
  3. ^ Roland Röhrich, Winfried Stadtmüller: Annual report 1971/72. Röntgen-Gymnasium Würzburg, Würzburg 1972, p. 26 ( class 9 e ).
  4. ^ Annual report 1975/76. Friedrich-Koenig-Gymnasium Würzburg, Würzburg 1976, p. 51.
  5. ^ Institute for Virology and Immunobiology at the Julius Maximilians University of Würzburg. Julius Maximilians University of Würzburg, September 21, 2015, accessed on March 3, 2016 .
  6. ^ Institute for Medical Radiation Science and Cell Research, Julius Maximilians University of Würzburg. Julius-Maximilians-Universität Würzburg, September 3, 2014, accessed on March 3, 2016 .
  7. Experimental Medicine - Ulm Medical Faculty. Medical Faculty of the University of Ulm, accessed on August 27, 2018 .
  8. Ulm Medical Faculty. Medical Faculty of the University of Ulm, accessed on March 3, 2016 .
  9. German Trauma Foundation eV - The Bureau and its members. Deutsche Traumastiftung eV, accessed on March 19, 2019 .